What do we mean by identifiability in mixed effects models? (2016)
Attributed to:
Rare disease use of clinical trial simulation for the chioce and optimization of study designs/Priomedchild Call/ER
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s10928-015-9459-4
PubMed Identifier: 26660913
Publication URI: http://europepmc.org/abstract/MED/26660913
Type: Journal Article/Review
Volume: 43
Parent Publication: Journal of pharmacokinetics and pharmacodynamics
Issue: 1
ISSN: 1567-567X